An interventional study of CardiAMP Cell Therapy System and Sham Treatment in Refractory Angina and Chronic Myocardial Ischemia, sponsored by BioCardia, Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by BioCardia, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in Angina Pectoris with a site in United States — 13 open to participants now, 17 under way, 2 of them phase 3. Angina Pectoris · United States.
Among the 113 studies in Angina Pectoris with a site in United States, this one is the 18th largest by planned enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2021, is one of 30 with no phase, reaches primary completion later than 0 of the 16 other live ones, and was the 86th registered.
454 studies on the registry are indexed under Angina Pectoris; 67 are open to participants now.
Browse Angina Pectoris studies →13 of the 113 studies in Angina Pectoris with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
University of Virginia · Sites in United States
Ages 18+ · Women only
University of South Florida · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18+ · Women only
XyloCor Therapeutics, Inc. · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Angina Pectoris studies recruiting now, 34 (74%) set no upper age limit and 1 (2%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 21 · Phase 3 14 · Phase 4 8
First in 2000; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 343 is above the median of 100 across 273 interventional studies indexed under Angina Pectoris.
Median enrollment 124 across the 73 interventional studies, 240 across the 39 observational. Of the 81 that completed or were terminated, 33 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 113 have an industry lead sponsor. The 10 most frequent:
BioCardia, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
BioCardia, Inc. has 1 study filed under Angina Pectoris — fewer than ten, so there is no comparison to draw.
7 of the studies in Angina Pectoris with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03789552Phase 3Tasly Pharmaceuticals, Inc.Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina | 2026-12 |
| NCT06424834Phase 3Stanford UniversityEfficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries | 2026-12 |
| NCT05786417Yale UniversityLIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions | 2027-05-30 |
| NCT07048808XyloCor Therapeutics, Inc.Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. | 2027-06-30 |
| NCT05634031Icahn School of Medicine at Mount SinaiImaging Coronary Microvascular Dysfunction (CMD) Study | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 113 studies in Angina Pectoris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment
Treatment Group:
Subjects treated with aBMC using the CardiAMP cell therapy system
Sham Control Group:
Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Other cardiac or vascular system or other health-related criteria which may be seen in a patient's history and physical examination.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roll-in phase: Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase. In the subsequent randomized phase: Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system.
Device: CardiAMP Cell Therapy System
Randomized phase: Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)
Other: Sham Treatment
The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
Change from Baseline in Total Exercise Time on the treadmill using the Modified Bruce Protocol
A superiority analysis with regards to change from Baseline in Total Exercise Time at the 6 months follow-up visit (using a Modified Bruce Protocol).
Time frame: Baseline and 6 months visit
Safety: overall survival at 6 months follow-up
A non-inferiority analysis of overall survival at 6-months will be made comparing the Treatment group to the Sham Control group using a non-inferiority margin of 10%.
Time frame: at 6 months follow-up
Safety: Total Major adverse cardiac events (MACE) at 6 months follow-up
A non-inferiority analysis with regard to Total Major Adverse Cardiac Events (MACE: defined as death, cardiac hospitalization, non-fatal myocardial infarction and stroke) at 12 month follow-up, as adjudicated by an independent clinical endpoint classification (CEC) committee with 10% margin.
Time frame: from randomisation to 6 months follow-up
Efficacy: Change from baseline in Total Exercise Time at 6 months follow-up
Superiority analysis with regards to change from baseline in Total Exercise Time on Exercise Tolerance Test (ETT) at 6 Month Follow-up Visit. Baseline (BL) is the average of (at least) two total exercise times measured during the screening period.
Time frame: Baseline and at 6 months follow-up
Efficacy: Change of angina frequency (per week) at 12 months follow-up
Superiority analysis with regards to change in angina frequency (episodes per week) at 12 month follow-up Visit versus baseline angina frequency (per week). Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline (screening period) and in the 4 weeks before the 12-month follow-up visits.
Time frame: Baseline and at 12 months follow-up
Efficacy: Change of Angina Frequency (per week) at 6 months follow-up
Superiority analysis with regards to change in angina frequency at 6 month follow-up visit versus baseline (expressed as angina frequency per week). Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline and in the 4 weeks before the 6-month follow-up visits.
Time frame: Baseline and at 6 months follow-up
Safety: Total Major adverse cardiac events (MACE) at 12 months follow-up
Superiority analysis with regards to incidence of MACE from Randomization until the end of the 24 month follow-up period
Time frame: From randomisation to 12 month follow-up
Efficacy: Percentage of patients with at least 1 Serious Adverse Event (SAE)
Superiority analysis with regards to percentage of participants with at least one SAE. From randomization until the end of the 12 month follow-up period.
Time frame: From randomization to 12 Months follow-up
Plan to share: No
Ran from Jun 2021 to primary completion in Feb 2025, 43 months.
Of 72 interventional studies with no phase under Angina Pectoris, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's 43 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioCardia, Inc.